Press releaseGlobe Newswire
Galectin Therapeutics
GALT · NASDAQ
$3.43−$0.065 (−1.86%)TodayMarket closed ·
Prev close $3.50
Latest news
- Press releaseGlobe Newswire
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
- NewsAvi Kapoor
Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On Tuesday
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releaseGlobe Newswire
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
- Press releaseGlobe Newswire
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseGlobe Newswire
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
- Press releaseGlobe Newswire
Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm
- Press releaseGlobe Newswire
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
- News
Galectin Therapeutics Option Alert: Jul 17 $5 Calls at the Ask: 3575 @ $0.45 vs 3177 OI; Earnings 3/30 Before Open [est] Ref=$3.015
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
- Press releaseGlobe Newswire
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
- Press releaseBusiness Wire
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm
- Press releaseGlobe Newswire
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releaseGlobe Newswire
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releasePRNewswire
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releaseGlobe Newswire
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update
- Press releaseGlobe Newswire
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
- NewsAvi Kapoor
Dow Surges Over 600 Points, Gold Jumps 1.5%
- NewsAvi Kapoor
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
- NewsAvi Kapoor
Dow Surges 100 Points, Carnival Earnings Top Views
- Press releaseGlobe Newswire
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
- Press releaseGlobe Newswire
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
- NewsAvi Kapoor
Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.